{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T10:36:44Z","timestamp":1771756604645,"version":"3.50.1"},"reference-count":97,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Clinics of North America"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.suc.2023.08.004","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T01:13:43Z","timestamp":1695172423000},"page":"11-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Current Use of Immunosuppression in Liver Transplantation"],"prefix":"10.1016","volume":"104","author":[{"given":"Michie","family":"Adjei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene K.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.suc.2023.08.004_bib1","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/00000658-196809000-00009","article-title":"Orthotopic homotransplantation of the human liver","volume":"168","author":"Starzl","year":"1968","journal-title":"Ann Surg"},{"issue":"8151","key":"10.1016\/j.suc.2023.08.004_bib2","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(79)92440-1","article-title":"Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers","volume":"2","author":"Calne","year":"1979","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.suc.2023.08.004_bib3","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0192-0561(79)90037-7","article-title":"Immunosuppression for organ grafting","volume":"1","author":"Calne","year":"1979","journal-title":"Int J Immunopharmacol"},{"issue":"Suppl 2","key":"10.1016\/j.suc.2023.08.004_bib4","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/ajt.16978","article-title":"OPTN\/SRTR 2020 Annual Data Report: Liver","volume":"22","author":"Kwong","year":"2022","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.suc.2023.08.004_bib5","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1600-6143.2009.02880.x","article-title":"The influence of induction therapy on graft and patient survival in patients with and without hepatitis C after liver transplantation","volume":"10","author":"Moonka","year":"2010","journal-title":"Am J Transplant"},{"issue":"12","key":"10.1016\/j.suc.2023.08.004_bib6","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1097\/TP.0b013e3181fecfcb","article-title":"Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data","volume":"90","author":"Cai","year":"2010","journal-title":"Transplantation"},{"issue":"12","key":"10.1016\/j.suc.2023.08.004_bib7","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1111\/ajt.15513","article-title":"The use of induction therapy in liver transplantation is highly variable and is associated with posttransplant outcomes","volume":"19","author":"Bittermann","year":"2019","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.suc.2023.08.004_bib8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/ajt.12962","article-title":"Differential rates of ischemic cholangiopathy and graft survival associated with induction therapy in DCD liver transplantation","volume":"15","author":"Halldorson","year":"2015","journal-title":"Am J Transplant"},{"issue":"2S1","key":"10.1016\/j.suc.2023.08.004_bib9","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1016\/j.ajt.2023.02.006","article-title":"OPTN\/SRTR 2021 Annual Data Report: Liver","volume":"23","author":"Kwong","year":"2023","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.suc.2023.08.004_bib10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/lt.25600","article-title":"Introducing the 2019 American Association for the Study of Liver Diseases Guidance on Alcohol-Associated Liver Disease","volume":"26","author":"Lucey","year":"2020","journal-title":"Liver Transpl"},{"issue":"3","key":"10.1016\/j.suc.2023.08.004_bib11","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/TP.0000000000002532","article-title":"Asian Liver Transplant Network Clinical Guidelines on Immunosuppression in Liver Transplantation","volume":"103","author":"Tan","year":"2019","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.suc.2023.08.004_bib12","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2015.10.006","article-title":"easloffice@easloffice.eu EAftSotLEa. EASL Clinical Practice Guidelines: Liver transplantation","volume":"64","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"19","key":"10.1016\/j.suc.2023.08.004_bib13","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa060068","article-title":"Rabbit antithymocyte globulin versus basiliximab in renal transplantation","volume":"355","author":"Brennan","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.suc.2023.08.004_bib14","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/j.1432-2277.2011.01250.x","article-title":"Outcome of induction immunosuppression for liver transplantation comparing anti-thymocyte globulin, daclizumab, and corticosteroid","volume":"24","author":"Uemura","year":"2011","journal-title":"Transpl Int"},{"issue":"5","key":"10.1016\/j.suc.2023.08.004_bib15","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.transproceed.2012.01.117","article-title":"Routine induction therapy in living donor liver transplantation prevents rejection but may promote recurrence of hepatitis C","volume":"44","author":"Ghanekar","year":"2012","journal-title":"Transplant Proc"},{"issue":"2","key":"10.1016\/j.suc.2023.08.004_bib16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/jlts.2002.30302","article-title":"Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial","volume":"8","author":"Neuhaus","year":"2002","journal-title":"Liver Transpl"},{"issue":"7","key":"10.1016\/j.suc.2023.08.004_bib17","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.gassur.2005.06.020","article-title":"Antithymocyte globulin induction therapy in hepatitis C-positive liver transplant recipients","volume":"9","author":"Horton","year":"2005","journal-title":"J\u00a0Gastrointest Surg"},{"issue":"11","key":"10.1016\/j.suc.2023.08.004_bib18","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1007\/s10620-014-3215-2","article-title":"Impact of anti-thymocyte globulin during immunosuppression induction in patients with hepatitis C after liver transplantation","volume":"59","author":"Garcia-Saenz-de-Sicilia","year":"2014","journal-title":"Dig Dis Sci"},{"issue":"7","key":"10.1016\/j.suc.2023.08.004_bib19","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/tri.12100","article-title":"Induction immunosuppression in liver transplantation: a review","volume":"26","author":"Turner","year":"2013","journal-title":"Transpl Int"},{"issue":"4","key":"10.1016\/j.suc.2023.08.004_bib20","first-page":"425","article-title":"Superior Patient and Graft Survival in Adult Liver Transplant with Rabbit Antithymocyte Globulin Induction: Experience with 595 Patients","volume":"15","author":"Montenovo","year":"2017","journal-title":"Exp Clin Transplant"},{"issue":"1","key":"10.1016\/j.suc.2023.08.004_bib21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/lt.25832","article-title":"Comparison of Clinical Outcomes of Induction Regimens in Patients Undergoing Liver Transplantation for Acute Liver Failure","volume":"27","author":"Anugwom","year":"2021","journal-title":"Liver Transpl"},{"issue":"5","key":"10.1016\/j.suc.2023.08.004_bib22","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1097\/TP.0000000000003904","article-title":"Induction Therapy With Antithymocyte Globulin and Delayed Calcineurin Inhibitor Initiation for Renal Protection in Liver Transplantation: A Multicenter Randomized Controlled Phase II-B Trial","volume":"106","author":"Nair","year":"2022","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.suc.2023.08.004_bib23","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1097\/TP.0000000000000477","article-title":"Steroid-free Liver Transplantation Using Rabbit Antithymocyte Globulin Induction in 500 Consecutive Patients","volume":"99","author":"Yoo","year":"2015","journal-title":"Transplantation"},{"issue":"7","key":"10.1016\/j.suc.2023.08.004_bib24","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/lt.21185","article-title":"Short-term induction therapy with anti-thymocyte globulin and delayed use of calcineurin inhibitors in orthotopic liver transplantation","volume":"13","author":"Soliman","year":"2007","journal-title":"Liver Transpl"},{"issue":"1","key":"10.1016\/j.suc.2023.08.004_bib25","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/lt.21309","article-title":"Preserving renal function in liver transplant recipients with rabbit anti-thymocyte globulin and delayed initiation of calcineurin inhibitors","volume":"14","author":"Bajjoka","year":"2008","journal-title":"Liver Transpl"},{"issue":"4","key":"10.1016\/j.suc.2023.08.004_bib26","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/01.tp.0000181192.13836.8c","article-title":"Induction with rabbit antithymocyte globulin versus induction with corticosteroids in liver transplantation: impact on recurrent hepatitis C virus infection","volume":"81","author":"Nair","year":"2006","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.suc.2023.08.004_bib27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/01.TP.0000164349.54297.95","article-title":"Preliminary results of a \"prope\" tolerogenic regimen with thymoglobulin pretreatment and hepatitis C virus recurrence in liver transplantation","volume":"80","author":"De Ruvo","year":"2005","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.suc.2023.08.004_bib28","first-page":"160","article-title":"Induction with Rabbit Antithymocyte Globulin following Orthotopic Liver Transplantation for Hepatitis C","volume":"2","author":"Saidi","year":"2011","journal-title":"Int J Organ Transplant Med"},{"issue":"8","key":"10.1016\/j.suc.2023.08.004_bib29","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.dld.2021.12.006","article-title":"Renal function after liver transplantation: Real-world experience with basiliximab induction and delayed reduced-dose tacrolimus","volume":"54","author":"Cederborg","year":"2022","journal-title":"Dig Liver Dis"},{"issue":"4","key":"10.1016\/j.suc.2023.08.004_bib30","first-page":"38","article-title":"Daclizumab withdrawn from the market worldwide","volume":"56","year":"2018","journal-title":"Drug Ther Bull"},{"issue":"12","key":"10.1016\/j.suc.2023.08.004_bib31","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1097\/00007890-200112270-00008","article-title":"Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection","volume":"72","author":"Sollinger","year":"2001","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.suc.2023.08.004_bib32","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0041-1345(03)00679-1","article-title":"ATG versus basiliximab induction therapy in renal allograft recipients receiving a dual immunosuppressive regimen: one-year results","volume":"35","author":"Tullius","year":"2003","journal-title":"Transplant Proc"},{"issue":"5","key":"10.1016\/j.suc.2023.08.004_bib33","doi-asserted-by":"crossref","first-page":"541","DOI":"10.5604\/01.3001.0012.2246","article-title":"Efficacy and safety of basiliximab as initial immunosuppression in liver transplantation: A single center study","volume":"19","author":"Hashim","year":"2020","journal-title":"Ann Hepatol"},{"issue":"5","key":"10.1016\/j.suc.2023.08.004_bib34","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.hpb.2020.09.012","article-title":"Randomized trial of steroid free immunosuppression with basiliximab induction in adult live donor liver transplantation (LDLT)","volume":"23","author":"Kathirvel","year":"2021","journal-title":"HPB (Oxford)"},{"issue":"2","key":"10.1016\/j.suc.2023.08.004_bib35","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1499-3872(16)60183-2","article-title":"Basiliximab application on liver recipients: a meta-analysis of randomized controlled trials","volume":"16","author":"Zhang","year":"2017","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"12","key":"10.1016\/j.suc.2023.08.004_bib36","doi-asserted-by":"crossref","first-page":"e13415","DOI":"10.1111\/ctr.13415","article-title":"Delayed calcineurin inhibitor introduction and renal outcomes in liver transplant recipients receiving basiliximab induction","volume":"32","author":"Lange","year":"2018","journal-title":"Clin Transplant"},{"issue":"1","key":"10.1016\/j.suc.2023.08.004_bib37","first-page":"7","article-title":"IL-2 Receptor Antagonist (Basiliximab) Is Associated with Rapid Fibrosis Progression in Patients with Recurrent Hepatitis C after Liver Transplantation Using Serial Biopsy Specimens","volume":"1","author":"Hanouneh","year":"2010","journal-title":"Int J Organ Transplant Med"},{"issue":"1","key":"10.1016\/j.suc.2023.08.004_bib38","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1399-0012.2004.00302.x","article-title":"Induction therapy with either anti-CD25 monoclonal antibodies or rabbit antithymocyte globulins in liver transplantation for hepatitis C","volume":"19","author":"Kamar","year":"2005","journal-title":"Clin Transplant"},{"issue":"1","key":"10.1016\/j.suc.2023.08.004_bib39","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/lt.22180","article-title":"Alemtuzumab induction in non-hepatitis C positive liver transplant recipients","volume":"17","author":"Levitsky","year":"2011","journal-title":"Liver Transpl"},{"issue":"2","key":"10.1016\/j.suc.2023.08.004_bib40","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5414\/CN109934","article-title":"Alemtuzumab induction for retransplantation after primary transplant with alemtuzumab induction","volume":"93","author":"Descourouez","year":"2020","journal-title":"Clin Nephrol"},{"issue":"7","key":"10.1016\/j.suc.2023.08.004_bib41","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1097\/01.TP.0000142674.78268.01","article-title":"Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus","volume":"78","author":"Marcos","year":"2004","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.suc.2023.08.004_bib42","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1097\/01.TP.0000116562.15920.43","article-title":"Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation","volume":"77","author":"Tzakis","year":"2004","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.suc.2023.08.004_bib43","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.transproceed.2004.12.157","article-title":"The impact of Campath 1H induction in adult liver allotransplantation","volume":"37","author":"Tryphonopoulos","year":"2005","journal-title":"Transplant Proc"},{"issue":"8","key":"10.1016\/j.suc.2023.08.004_bib44","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/phar.2716","article-title":"Consensus recommendations for use of maintenance immunosuppression in solid organ transplantation: Endorsed by the American College of Clinical Pharmacy, American Society of Transplantation, and the International Society for Heart and Lung Transplantation","volume":"42","author":"Nelson","year":"2022","journal-title":"Pharmacotherapy"},{"issue":"7","key":"10.1016\/j.suc.2023.08.004_bib45","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1097\/TXD.0000000000000800","article-title":"Center-driven and Clinically Driven Variation in US Liver Transplant Maintenance Immunosuppression Therapy: A National Practice Patterns Analysis","volume":"4","author":"Nazzal","year":"2018","journal-title":"Transplant Direct"},{"issue":"1","key":"10.1016\/j.suc.2023.08.004_bib46","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1600-6143.2006.01576.x","article-title":"Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years","volume":"7","author":"O'Grady","year":"2007","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.suc.2023.08.004_bib47","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/j.1600-6143.2006.01360.x","article-title":"Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis","volume":"6","author":"McAlister","year":"2006","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.suc.2023.08.004_bib48","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1432-2277.2008.00796.x","article-title":"Calcineurin inhibitor minimization protocols in liver transplantation","volume":"22","author":"Farkas","year":"2009","journal-title":"Transpl Int"},{"issue":"9","key":"10.1016\/j.suc.2023.08.004_bib49","doi-asserted-by":"crossref","first-page":"e24387","DOI":"10.1371\/journal.pone.0024387","article-title":"Calcineurin-inhibitor minimization in liver transplant patients with calcineurin-inhibitor-related renal dysfunction: a meta-analysis","volume":"6","author":"Kong","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.suc.2023.08.004_bib50","first-page":"CD007606","article-title":"Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients","volume":"4","author":"Fairfield","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"21","key":"10.1016\/j.suc.2023.08.004_bib51","first-page":"2177","article-title":"Sirolimus approved with renal transplant indication","volume":"56","author":"Miller","year":"1999","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.suc.2023.08.004_bib52","first-page":"913094","article-title":"A\u00a0Decade of Experience Using mTor Inhibitors in Liver Transplantation","volume":"2011","author":"Campsen","year":"2011","journal-title":"J\u00a0Transplant"},{"issue":"1","key":"10.1016\/j.suc.2023.08.004_bib53","doi-asserted-by":"crossref","first-page":"30","DOI":"10.6002\/ect.2011.0086","article-title":"Long-term outcome of conversion to sirolimus monotherapy after liver transplant","volume":"10","author":"Uhlmann","year":"2012","journal-title":"Exp Clin Transplant"},{"issue":"11","key":"10.1016\/j.suc.2023.08.004_bib54","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1111\/j.1600-6143.2012.04212.x","article-title":"Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial","volume":"12","author":"De Simone","year":"2012","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.suc.2023.08.004_bib55","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1111\/ajt.14212","article-title":"Efficacy and Safety of Everolimus and Mycophenolic Acid With Early Tacrolimus Withdrawal After Liver Transplantation: A Multicenter Randomized Trial","volume":"17","author":"Saliba","year":"2017","journal-title":"Am J Transplant"},{"issue":"11","key":"10.1016\/j.suc.2023.08.004_bib56","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1111\/liv.15396","article-title":"Five-year outcomes in liver transplant patients receiving everolimus with or without a calcineurin inhibitor: Results from the CERTITUDE study","volume":"42","author":"Saliba","year":"2022","journal-title":"Liver Int"},{"issue":"7","key":"10.1016\/j.suc.2023.08.004_bib57","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1111\/j.1600-6143.2012.04049.x","article-title":"A\u00a0randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation--PROTECT","volume":"12","author":"Fischer","year":"2012","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.suc.2023.08.004_bib58","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/lt.23658","article-title":"Calcineurin inhibitor-free mycophenolate mofetil\/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial","volume":"19","author":"Teperman","year":"2013","journal-title":"Liver Transpl"},{"issue":"6","key":"10.1016\/j.suc.2023.08.004_bib59","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/lt.26298","article-title":"Early Everolimus-Facilitated Reduced Tacrolimus in Liver Transplantation: Results From the Randomized HEPHAISTOS Trial","volume":"28","author":"Nashan","year":"2022","journal-title":"Liver Transpl"},{"issue":"9637","key":"10.1016\/j.suc.2023.08.004_bib60","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.suc.2023.08.004_bib61","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/ctr.12357","article-title":"The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy","volume":"28","author":"Klintmalm","year":"2014","journal-title":"Clin Transplant"},{"issue":"1","key":"10.1016\/j.suc.2023.08.004_bib62","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/TP.0000000000000965","article-title":"Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial","volume":"100","author":"Geissler","year":"2016","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.suc.2023.08.004_bib63","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/SLA.0000000000004280","article-title":"mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors","volume":"272","author":"Schnitzbauer","year":"2020","journal-title":"Ann Surg"},{"issue":"5","key":"10.1016\/j.suc.2023.08.004_bib64","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/TP.0000000000002147","article-title":"International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients","volume":"102","author":"Charlton","year":"2018","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.suc.2023.08.004_bib65","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.12872","article-title":"Everolimus with early withdrawal or reduced-dose calcineurin inhibitors improves renal function in liver transplant recipients: A systematic review and meta-analysis","volume":"31","author":"Lin","year":"2017","journal-title":"Clin Transplant"},{"issue":"2","key":"10.1016\/j.suc.2023.08.004_bib66","first-page":"184","article-title":"Three-year results of renal function in liver transplant recipients on low-dose sirolimus and tacrolimus: a multicenter, randomized, controlled trial","volume":"29","author":"Mulder","year":"2023","journal-title":"Liver Transpl"},{"issue":"10","key":"10.1016\/j.suc.2023.08.004_bib67","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1016\/j.transproceed.2011.10.044","article-title":"Long-term outcomes of calcineurin inhibitor withdrawal for post-liver transplant renal dysfunction","volume":"43","author":"Mackay","year":"2011","journal-title":"Transplant Proc"},{"issue":"10","key":"10.1016\/j.suc.2023.08.004_bib68","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/lt.23704","article-title":"Liver transplantation and autoimmune liver diseases","volume":"19","author":"Liberal","year":"2013","journal-title":"Liver Transpl"},{"issue":"4","key":"10.1016\/j.suc.2023.08.004_bib69","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/apt.13894","article-title":"Systematic review: recurrent autoimmune liver diseases after liver transplantation","volume":"45","author":"Montano-Loza","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.suc.2023.08.004_bib70","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1399-0012.2005.00471.x","article-title":"Long-term follow-up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients","volume":"20","author":"Jacob","year":"2006","journal-title":"Clin Transplant"},{"issue":"7","key":"10.1016\/j.suc.2023.08.004_bib71","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1097\/TXD.0000000000000693","article-title":"Outcomes of Liver Transplant Recipients With Autoimmune Liver Disease Using Long-Term Dual Immunosuppression Regimen Without Corticosteroid","volume":"3","author":"Satapathy","year":"2017","journal-title":"Transplant Direct"},{"issue":"12","key":"10.1016\/j.suc.2023.08.004_bib72","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/j.cgh.2017.06.001","article-title":"Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis","volume":"15","author":"Efe","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.suc.2023.08.004_bib73","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.transproceed.2005.03.145","article-title":"Withdrawal of steroids: a randomized prospective study of prednisone and tacrolimus versus mycophenolate mofetil and tacrolimus in liver transplant recipients with autoimmune hepatitis","volume":"37","author":"Junge","year":"2005","journal-title":"Transplant Proc"},{"issue":"2","key":"10.1016\/j.suc.2023.08.004_bib74","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/01.TP.0000438635.44461.2e","article-title":"Safety of belatacept bridging immunosuppression in hepatitis C-positive liver transplant recipients with renal dysfunction","volume":"97","author":"LaMattina","year":"2014","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.suc.2023.08.004_bib75","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1111\/ajt.12810","article-title":"Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study","volume":"14","author":"Klintmalm","year":"2014","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.suc.2023.08.004_bib76","doi-asserted-by":"crossref","first-page":"e1076","DOI":"10.1097\/TXD.0000000000001076","article-title":"Belatacept Treatment of Recurrent Late-onset T Cell-mediated Rejection\/Antibody-mediated Rejection With De Novo Donor-specific Antibodies in a Liver Transplant Patient","volume":"8","author":"Klintmalm","year":"2022","journal-title":"Transplant Direct"},{"issue":"9","key":"10.1016\/j.suc.2023.08.004_bib77","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/lt.25785","article-title":"Successful Pregnancy in a Liver Transplant Recipient on Belatacept","volume":"26","author":"Klintmalm","year":"2020","journal-title":"Liver Transpl"},{"issue":"11","key":"10.1016\/j.suc.2023.08.004_bib78","doi-asserted-by":"crossref","first-page":"e780","DOI":"10.1097\/TXD.0000000000001229","article-title":"Belatacept Conversion in Kidney After Liver Transplantation","volume":"7","author":"Cristea","year":"2021","journal-title":"Transplant Direct"},{"issue":"3","key":"10.1016\/j.suc.2023.08.004_bib79","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1399-0012.2008.00944.x","article-title":"Immunosuppression withdrawal improves long-term metabolic parameters, cardiovascular risk factors and renal function in liver transplant patients","volume":"23","author":"Pons","year":"2009","journal-title":"Clin Transplant"},{"issue":"4","key":"10.1016\/j.suc.2023.08.004_bib80","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jhep.2013.04.003","article-title":"Immunosuppression minimization vs. complete drug withdrawal in liver transplantation","volume":"59","author":"Londo\u00f1o","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.suc.2023.08.004_bib81","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1001\/jama.2011.2014","article-title":"Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants","volume":"307","author":"Feng","year":"2012","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.suc.2023.08.004_bib82","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1002\/hep.26426","article-title":"Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients","volume":"58","author":"Ben\u00edtez","year":"2013","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.suc.2023.08.004_bib83","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1111\/ajt.15205","article-title":"Outcomes of immunosuppression minimization and withdrawal early after liver transplantation","volume":"19","author":"Shaked","year":"2019","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.suc.2023.08.004_bib84","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/lt.25717","article-title":"Pregnancy in Liver Transplantation","volume":"26","author":"Rahim","year":"2020","journal-title":"Liver Transpl"},{"issue":"7","key":"10.1016\/j.suc.2023.08.004_bib85","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.cgh.2018.11.055","article-title":"Outcomes of Pregnancy in Recipients of Liver Transplants","volume":"17","author":"Kamarajah","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.suc.2023.08.004_bib86","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1097\/01.tp.0000252683.74584.29","article-title":"Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus","volume":"82","author":"Sifontis","year":"2006","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.suc.2023.08.004_bib87","first-page":"42","article-title":"Update on the Teratogenicity of Maternal Mycophenolate Mofetil","volume":"4","author":"Coscia","year":"2015","journal-title":"J\u00a0Pediatr Genet"},{"issue":"2","key":"10.1016\/j.suc.2023.08.004_bib88","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/MOT.0000000000000275","article-title":"Prevention and treatment of liver allograft antibody-mediated rejection and the role of the 'two-hit hypothesis'","volume":"21","author":"Kim","year":"2016","journal-title":"Curr Opin Organ Transplant"},{"issue":"10","key":"10.1016\/j.suc.2023.08.004_bib89","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1111\/ajt.13909","article-title":"Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection","volume":"16","author":"Demetris","year":"2016","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.suc.2023.08.004_bib90","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.gtc.2017.01.005","article-title":"Antibody-Mediated Rejection After Liver Transplant","volume":"46","author":"Lee","year":"2017","journal-title":"Gastroenterol Clin North Am"},{"issue":"2","key":"10.1016\/j.suc.2023.08.004_bib91","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/jcph.1963","article-title":"Antibody-Mediated Rejection in Adult Liver Transplant Recipients: A Case Series and Literature Review","volume":"62","author":"Baradaran","year":"2022","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.suc.2023.08.004_bib92","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000170864","article-title":"Therapeutic strategies in management of the highly HLA-sensitized and ABO-incompatible transplant recipients","volume":"162","author":"Jordan","year":"2009","journal-title":"Contrib Nephrol"},{"issue":"5","key":"10.1016\/j.suc.2023.08.004_bib93","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.jhep.2021.07.027","article-title":"Antibody-mediated rejection of the liver allograft: An update and a clinico-pathological perspective","volume":"75","author":"Lee","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"9","key":"10.1016\/j.suc.2023.08.004_bib94","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/hepr.13643","article-title":"The efficacy of rituximab treatment for antibody-mediated rejection in liver transplantation: A retrospective Japanese nationwide study","volume":"51","author":"Sakamoto","year":"2021","journal-title":"Hepatol Res"},{"issue":"1","key":"10.1016\/j.suc.2023.08.004_bib95","doi-asserted-by":"crossref","DOI":"10.1111\/petr.12791","article-title":"Acute antibody-mediated rejection in ABO-compatible pediatric liver transplant recipients: case series and review of the literature","volume":"21","author":"Wozniak","year":"2017","journal-title":"Pediatr Transplant"},{"issue":"10","key":"10.1016\/j.suc.2023.08.004_bib96","doi-asserted-by":"crossref","first-page":"e491","DOI":"10.1097\/TXD.0000000000000932","article-title":"Bortezomib Against Refractory Antibody-Mediated Rejection After ABO-Incompatible Living-Donor Liver Transplantation: Dramatic Effect in Acute-Phase?","volume":"5","author":"Tajima","year":"2019","journal-title":"Transplant Direct"},{"issue":"1","key":"10.1016\/j.suc.2023.08.004_bib97","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.transproceed.2021.11.022","article-title":"Refractory Acute Antibody Mediated Rejection in Liver Transplant After Desensitization of Preformed Donor Specific Antibody-Validity of Bortezomib and Everolimus: A Case Report","volume":"54","author":"Komagome","year":"2022","journal-title":"Transplant Proc"}],"container-title":["Surgical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003961092300138X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003961092300138X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T11:16:28Z","timestamp":1758539788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003961092300138X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":97,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S003961092300138X"],"URL":"https:\/\/doi.org\/10.1016\/j.suc.2023.08.004","relation":{},"ISSN":["0039-6109"],"issn-type":[{"value":"0039-6109","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Use of Immunosuppression in Liver Transplantation","name":"articletitle","label":"Article Title"},{"value":"Surgical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.suc.2023.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}